Beijing Guoke Brain-Computer Intelligence Technology Co., Ltd. has closed a seed financing round worth tens of millions of RMB, led by Sinovation Ventures with follow-on participation from Houtian Capital and Wanfang Capital.
Guoke Brain-Computer was founded in June 2026 as a technology spin‑out from the Institute of Automation of the Chinese Academy of Sciences. The company focuses on R&D and industrialization of non‑invasive, wearable two‑way brain–computer interface (BCI) technology. Its product roadmap includes three hardware pipelines—forehead‑stick, headband and a high‑density wearable BCI platform—targeting rapid screening of brain diseases, detection and regulation of mental and sleep disorders, and brain–computer interaction scenarios.
Guoke Brain-Computer’s technology and product strategy
The company positions itself as a developer of a full‑stack wearable non‑invasive two‑way closed‑loop BCI, centering on a “wearable hardware + AI” technical line. Guoke says it has built independent capabilities in three areas: signal detection (reading), neural regulation (writing) and EEG decoding, and aims to deliver an end‑side intelligent agent that integrates detection, decoding and regulation.
Guoke frames its work as an answer to what it calls the industry’s “four noes” dilemma—devices that are inconvenient, unstable, unintelligent and facing non‑rigid demand. To address inconvenience, products use micro‑miniaturized wearable designs, integrate closed‑loop functions of detection, decoding and regulation, and adopt measures such as multiple shielding, low power consumption and multi‑dimensional degrees of freedom to make devices compact and easy to wear.
To tackle instability, the company uses an integrated “hardware + AI” approach to realize end‑side “sensing and computing integration,” which it says mitigates brain‑signal drift caused by differing device models and removes cross‑dataset barriers when building large EEG models. To overcome unintelligent solutions, Guoke deploys an end‑side hybrid MCU+FPGA design to deliver immediate, real‑time interpretation—avoiding workflows that export raw data for later offline analysis—and presents real‑time results in use cases including psychiatric diagnosis and sleep monitoring.
For the problem of non‑rigid demand, Guoke pragmatically targets medical and health scenarios—diagnosis, regulation and treatment of mental health and sleep disorders—where demand is rigid. The company argues that mass deployment in these scenarios will produce consistent, structured data that can underpin large EEG models and make later expansion into non‑medical applications feasible.
The firm also highlights a fundamental challenge in BCI development: brain functional signals and activity patterns vary widely, and identical brains measured by different devices can produce significantly different signals. Guoke states this is why large AI models popular in computer vision have not translated directly to neuroscience. Its wearable “hardware + AI” strategy is presented as a solution to that data and device heterogeneity by integrating signal detection, decoding and regulation at the device level.
Guoke describes “integration” as the basis for intelligent BCI devices and “miniaturization” as a prerequisite for broad scenario deployment. The company says achieving both requires coordinated innovation across small size, high precision, strong computing power, low power consumption and ease of wear—elements it cites as central to its development philosophy. Looking ahead, Guoke plans to focus on three core dimensions: medical health, natural interaction and brain–computer intelligent agents, with the aim of moving BCI toward practical applications and wider adoption.
After closing the seed round, Guoke says it will expand its hardware and algorithm teams, advance medical device registration, deepen clinical cooperative research, continuously improve its “wearable hardware + AI” capabilities and promote industrialized implementation of non‑invasive wearable two‑way BCI products.
